Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First in Human Randomized, Double-Blind, Placebo Controlled Single Ascending Dose (SAD) Phase 1 Study to Determine Safety, Tolerability, and Pharmacokinetics of 4ET1103 in Healthy Volunteers

NCT07586514 is registered in ClinicalTrials.gov with 4E Therapeutics as lead sponsor.

NCT NCT07586514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07586514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First in Human Randomized, Double-Blind, Placebo Controlled Single Ascending Dose (SAD) Phase 1 Study to Determine Safety, Tolerability, and Pharmacokinetics of 4ET1103 in Healthy Volunteers
Lead sponsor
4E Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
April 18, 2025
Completion date
August 18, 2025
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuropathic pain